Antibody or chimeric antigen receptor which targets Claudin 18.2
US12312402B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 28, 2020 |
| Grant date | May 27, 2025 |
| Priority date | — |
| Expiry date | Oct 22, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/53
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are an antibody or an antigen binding fragment or chimeric antigen receptor thereof which binds to Claudin18.2, and a preparation method and a use. The chimeric antigen receptor sequentially comprises the antibody or the antigen binding fragment thereof which binds to the Claudin18.2 antigen, an extracellular hinge region, a transmembrane region and an intracellular signaling region. The antibody or the antigen binding fragment or chimeric antigen receptor thereof has stronger affinity and killing capability for cells secreting Claudin18.2, and a better tumor inhibiting effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.